|
64
|
231
|
4quyE |
Ycp beta5-a49s-mutant |
|
64
|
231
|
4qv4E |
Ycp beta5-m45t mutant |
|
71
|
212
|
4qz4K |
Ycp beta5-a49s mutant in complex with the epoxyketone inhibitor onx 0914 |
|
60
|
196
|
4qw0N |
Ycp beta5-a49t-a50v-double mutant in complex with bortezomib |
|
68
|
233
|
4qv4M |
Ycp beta5-m45t mutant |
|
70
|
244
|
4qvwB |
Ycp beta5-a49s-mutant in complex with bortezomib |
|
58
|
204
|
4qlvI |
Ycp in complex with tripeptidic epoxyketone inhibitor 17 |
|
57
|
204
|
4qv7I |
Ycp beta5-a50v mutant |
|
66
|
241
|
4r17G |
Ligand-induced aziridine-formation at subunit beta5 of the yeast 20s proteasome |
|
71
|
240
|
4qvqC |
Ycp beta5-m45i mutant in complex with bortezomib |
|
60
|
196
|
4quxN |
Ycp beta5-a49t-mutant |
|
59
|
226
|
4qvwH |
Ycp beta5-a49s-mutant in complex with bortezomib |
|
71
|
240
|
4qwxC |
Ycp in complex with the epoxyketone inhibitor onx 0914 |
|
63
|
241
|
4qw6G |
Ycp beta5-m45v mutant in complex with carfilzomib |
|
60
|
231
|
4qvmE |
Ycp beta5-m45a mutant in complex with bortezomib |
|
64
|
231
|
4qvwE |
Ycp beta5-a49s-mutant in complex with bortezomib |
|
71
|
243
|
4qluF |
Ycp in complex with tripeptidic epoxyketone inhibitor 9 |
|
67
|
242
|
4qvyD |
Ycp beta5-a49t-mutant in complex with bortezomib |
|
73
|
243
|
4qz1F |
Ycp beta5-m45t mutant in complex with the epoxyketone inhibitor onx 0914 |
|
58
|
243
|
4r67D |
Human constitutive 20s proteasome in complex with carfilzomib |
|
74
|
212
|
4qz5K |
Ycp beta5-a49t-mutant in complex with onx 0914 |
|
62
|
195
|
4qwrJ |
Ycp beta5-c52f mutant in complex with carfilzomib |
|
72
|
243
|
4qzwF |
Ycp beta5-c52f mutant in complex with the epoxyketone inhibitor onx 0914 |
|
59
|
196
|
4qwxN |
Ycp in complex with the epoxyketone inhibitor onx 0914 |
|
64
|
231
|
4qvlE |
Ycp in complex with bortezomib |
|
67
|
242
|
4qwiD |
Ycp beta5-a49s-mutant in complex with carfilzomib |
|
61
|
196
|
4qv9N |
Ycp beta5-c63f mutant |
|
69
|
242
|
4r02D |
Ycp in complex with bsc4999 (alpha-keto phenylamide) |
|
61
|
196
|
4qw5N |
Ycp beta5-m45a mutant in complex with carfilzomib |
|
71
|
244
|
4qvpB |
Ycp beta5-m45t mutant in complex with bortezomib |
|
58
|
226
|
4qv3H |
Ycp beta5-m45v mutant |
|
59
|
202
|
4r3oH |
Human constitutive 20s proteasome |
|
62
|
241
|
4qvmG |
Ycp beta5-m45a mutant in complex with bortezomib |
|
68
|
250
|
4qwjA |
Ycp beta5-a49t-mutant in complex with carfilzomib |
|
69
|
243
|
4qwgF |
Ycp beta5-a49v mutant in complex with carfilzomib |
|
59
|
226
|
4qvmH |
Ycp beta5-m45a mutant in complex with bortezomib |
|
65
|
242
|
4qzxD |
Ycp beta5-c63f mutant in complex with the epoxyketone inhibitor onx 0914 |
|
57
|
204
|
4qz0I |
Ycp beta5-m45v mutant in complex with the epoxyketone inhibitor onx 0914 |
|
68
|
233
|
4qvmM |
Ycp beta5-m45a mutant in complex with bortezomib |
|
70
|
240
|
4qluC |
Ycp in complex with tripeptidic epoxyketone inhibitor 9 |
|
58
|
226
|
4r18H |
Ligand-induced lys33-thr1 crosslinking at subunit beta5 of the yeast 20s proteasome |
|
67
|
240
|
4qz1C |
Ycp beta5-m45t mutant in complex with the epoxyketone inhibitor onx 0914 |
|
56
|
204
|
4qwjI |
Ycp beta5-a49t-mutant in complex with carfilzomib |
|
73
|
240
|
4quxC |
Ycp beta5-a49t-mutant |
|
57
|
204
|
4qzzI |
Ycp in complex with omuralide |
|
68
|
240
|
4qz5C |
Ycp beta5-a49t-mutant in complex with onx 0914 |
|
59
|
196
|
4qvqN |
Ycp beta5-m45i mutant in complex with bortezomib |
|
60
|
196
|
4qz3N |
Ycp beta5-a49v mutant in complex with the epoxyketone inhibitor onx 0914 |
|
62
|
231
|
4qw0E |
Ycp beta5-a49t-a50v-double mutant in complex with bortezomib |
|
61
|
196
|
4qw4N |
Ycp in complex with carfilzomib |
